代偿期肝硬化HVPG≥20 mmHg患者的临床失代偿与结局
本研究对741例代偿期肝硬化且HVPG≥6 mmHg的患者随访,按基线HVPG分为低(6-<12)、中(12-<20)、高(≥20 mmHg)三组。高HVPG组首次临床失代偿更早、更频繁且死亡率更高,基线HVPG是失代偿的独立预测因子,HVPG≥20 mmHg者应视为高危代偿期肝硬化。
要点
- 代偿期肝硬化HVPG≥20 mmHg者首次失代偿更早、更频繁,死亡率更高。
- 基线HVPG≥12至<20 mmHg和≥20 mmHg均独立预测临床失代偿。
- HVPG≥20 mmHg患者应标记为高危代偿期肝硬化并尽早干预降低门脉压力。
核心结论
- 代偿期肝硬化患者HVPG≥20 mmHg独立预测更早、更频繁的临床失代偿和不良结局。
- 该类患者应标记为高危代偿期肝硬化,并尽早启动有效降低门脉压力的干预以改善长期结局。
研究设计与样本
- 连续纳入741例HVPG≥6 mmHg的代偿期肝硬化患者,随访3-6个月观察临床失代偿发生。
- 按基线HVPG分为低HVPG组(6至<12 mmHg,n=163)、中HVPG组(12至<20 mmHg,n=437)和高HVPG组(≥20 mmHg,n=141)。
- 分析各组首次临床失代偿的预测因素、卡维地洛的HVPG应答及死亡率。
主要发现
- 平均随访1.6±0.4年期间217例(29.3%)发生临床失代偿,发生者基线HVPG更高(17.02±4.79 vs 14.28±4.86,P<0.001)。
- 高HVPG组首次失代偿早于低、中HVPG组(1.3±0.7年 vs 1.5±0.6年和1.6±0.5年,P=0.02),发生率更高(44.7% vs 11%和31.1%,P<0.01),死亡率更高。
- 与低HVPG组相比,高HVPG组NASH肝硬化更多(35.5% vs 19.6%,P=0.001),肝硬度值更高(45.06±20.46 vs 20.09±5.47 kPa,P<0.001),血小板计数更低(113.37±72.57 vs 151.7±87.30/cmm,P<0.001)。
- HVPG≥12 mmHg者接受卡维地洛,部分患者9.3±2.4个月后复查HVPG,应答率(HVPG降低≥20%或<12 mmHg)为31.6%(中HVPG组44.9%>高HVPG组22.2%,P<0.05)。
- 基线HVPG(≥12至<20 mmHg:风险比2.73;≥20 mmHg:风险比4.48,P<0.001)独立预测临床失代偿。
临床怎么用
- 对代偿期肝硬化患者应评估HVPG,HVPG≥20 mmHg者标记为高危代偿期肝硬化。
- 高危患者应尽早启动有效降低门脉压力的干预,以改善长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepatic venous pressure gradient (HVPG) of ≥10 mm Hg predicts clinical decompensation (CD) in compensated cirrhosis. A proportion of cirrhotic patients at presentation have high HVPG (≥20 mm Hg) and are compensated. The natural history, spectrum of CD, and mortality in this group is largely unknown. METHODS: Consecutive compensated cirrhotic patients with HVPG ≥6 mm Hg (n = 741) were followed up for 3-6 months for the development of any CD. Patients were classified based on the baseline HVPG (6 to <12 mm Hg [low HVPG, Gr.A, n = 163], 12 to <20 mm Hg [intermediate HVPG, Gr.B, n = 437] and ≥20 mm Hg [high HVPG, Gr.C, n = 141]). We analyzed the predictors of first CD, HVPG response to carvedilol, and mortality in these groups. RESULTS: CD developed in 217 (29.3%) patients during a mean follow-up of 1.6 ± 0.4 years, and those who developed CD had higher baseline HVPG (17.02 ± 4.79 vs 14.28 ± 4.86; P < 0.001). First CD was seen earlier (1.3 ± 0.7 years vs 1.5 ± 0.6 years and 1.6 ± 0.5 years, P = 0.02) and more frequently (44.7% vs 11% and 31.1%, P < 0.01) in high HVPG groups compared with low and intermediate HVPG groups, with higher mortality rates. Patients in the high HVPG group compared with the low HVPG group more often had NASH-cirrhosis (35.5% vs 19.6%; P 0.001), higher liver stiffness values (45.06 ± 20.46 vs 20.09 ± 5.47 kPa, P < 0.001), and lower platelet counts (113.37 ± 72.57 vs 151.7 ± 87.30/cmm, P < 0.001). Patients with HVPG ≥12 mm Hg received carvedilol, and a repeat HVPG performed in a proportion after 9.3 ± 2.4 months showed response (≥20% reduction in HVPG or <12 mm Hg) in 31.6% patients (Gr. B, 44.9% > Gr. C, 22.2%, P < 0.05). Baseline HVPG (HVPG ≥12 to <20 mm Hg [Hazard ratio: 2.73] and HVPG ≥20 mm Hg [Hazard ratio: 4.48], P < 0.001) independently predicted CD. DISCUSSION: HVPG ≥20 mm Hg in patients with compensated cirrhosis independently predicts early and more frequent CD and poor outcomes. These patients should be labeled as "high-risk compensated cirrhosis," and early and effective interventions to reduce portal pressure should be initiated to improve long-term outcomes.
引用
- Jindal A, Bhardwaj A, Kumar G, et al. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. Am J Gastroenterol. 2020. PMID: 32453061. doi:10.14309/ajg.0000000000000653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。